Investigational drug · Phase 2
VSJ-110
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dry Eye.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "VSJ-110"
First trial start
2025
Oct 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VSJ-110", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye
Approved drugs for the same conditions: Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "VSJ-110" as an intervention, largest first.
- An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyePivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT07179055 · 160 participants (planned) · Start Oct 2025 · Primary completion Sep 2026
Drug: VSJ-110; Placebo · For: Dry Eye
Sites: Newport Beach, California; Andover, Massachusetts; Shelby, North Carolina · 5 sites in all
Vanda PharmaceuticalsIndustry
NCT04622345 · 47 participants · Start Nov 21, 2020 · Primary completion May 22, 2021
Drug: VSJ-110; Placebo · For: Allergic Conjunctivitis
Sites: Andover, Massachusetts
- A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeStatus unknown
Vanda PharmaceuticalsIndustry
NCT06296966 · 40 participants (planned) · Start Feb 29, 2024 · Primary completion Jul 2024
Drug: VSJ-110; Placebo · For: Dry Eye
Sites: Andover, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Dry Eye
- CAM-101Elate Ocular, FD hPLPhase 31 trial
Cambium Bio Limited · Dry Eye Disease, Dry Eye, Dry Eyes Chronic
- SJP-0132Phase 31 trial
Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. · Dry Eye
- VVN001Phase 31 trial
VivaVision Biotech, Inc · Dry Eye
- 0.25% RCI001RCI001Phase 22 trials
ORA, Inc. · Dry Eye Disease (DED), Dry Eye
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- BTV100Phase 21 trial
BioTheraVision, Inc. · Dry Eye
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.